semaglutide prostate cancer ESMO 2025: BULLSEYE: 177Lu-PSMA-617 in Oligometastatic Hormone Sensitive Neoadjuvant 177Lutetium-PSMA-617 Radioligand Therapy for
Pay in 4 interest-free payments of $6.53 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



























